Aspen Pharmacare Holdings Ltd. (APNHY)
5.36
-0.18
(-3.16%)
USD |
OTCM |
Dec 15, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.380B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -41.88% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.9968 |
| Price to Book Value | -- |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.1208 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 71.29% |
Profile
| Aspen Pharmacare Holdings Ltd. manufactures and supplies branded and generic pharmaceutical products. It operates through the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals segment consists of the following business sub segments: Sterile Focused Brands, which includes the Anaesthetics and Thrombosis portfolios; and Regional Brands, which are products that are managed on a regional basis. The Manufacturing segment focuses on the following business sub segments: Active Pharmaceutical Ingredients, which involved in API Chemicals business and non-heparin biochemical API business; Heparin, which refers to the full value chain contribution from all heparin containing products; FDF Steriles, which includes all FDF sterile sales; and FDF Other, which consists of all non-sterile FDF products. The company was founded by Michael Guy Attridge and Stephen Bradley Saad in 1850 and is headquartered in Durban, South Africa. |
| URL | http://www.aspenpharma.com |
| Investor Relations URL | https://www.aspenpharma.com/investor-information/ |
| HQ State/Province | KwaZulu-Natal |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 03, 2026 |
| Last Earnings Release | Sep. 03, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Oct. 03, 2025 |
Ratings
Profile
| Aspen Pharmacare Holdings Ltd. manufactures and supplies branded and generic pharmaceutical products. It operates through the Commercial Pharmaceuticals and Manufacturing segments. The Commercial Pharmaceuticals segment consists of the following business sub segments: Sterile Focused Brands, which includes the Anaesthetics and Thrombosis portfolios; and Regional Brands, which are products that are managed on a regional basis. The Manufacturing segment focuses on the following business sub segments: Active Pharmaceutical Ingredients, which involved in API Chemicals business and non-heparin biochemical API business; Heparin, which refers to the full value chain contribution from all heparin containing products; FDF Steriles, which includes all FDF sterile sales; and FDF Other, which consists of all non-sterile FDF products. The company was founded by Michael Guy Attridge and Stephen Bradley Saad in 1850 and is headquartered in Durban, South Africa. |
| URL | http://www.aspenpharma.com |
| Investor Relations URL | https://www.aspenpharma.com/investor-information/ |
| HQ State/Province | KwaZulu-Natal |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Mar. 03, 2026 |
| Last Earnings Release | Sep. 03, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Oct. 03, 2025 |